

# James I Mullins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4531679/publications.pdf>

Version: 2024-02-01

231  
papers

19,721  
citations

8755

75  
h-index

12946

131  
g-index

234  
all docs

234  
docs citations

234  
times ranked

12883  
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV transmission patterns among transgender women, their cisgender male partners, and cisgender MSM in Lima, Peru: A molecular epidemiologic and phylodynamic analysis. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100121.	2.6	3
2	CRISPR/Cas9-Mediated Insertion of HIV Long Terminal Repeat within <i>BACH2</i> Promotes Expansion of T Regulatory-like Cells. <i>Journal of Immunology</i> , 2022, 208, 1700-1710.	0.8	4
3	Droplet-microfluidics-assisted sequencing of HIV proviruses and their integration sites in cells from people on antiretroviral therapy. <i>Nature Biomedical Engineering</i> , 2022, 6, 1004-1012.	22.5	21
4	Intra-host changes in Kaposi sarcoma-associated herpesvirus genomes in Ugandan adults with Kaposi sarcoma. <i>PLoS Pathogens</i> , 2021, 17, e1008594.	4.7	9
5	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	27.0	270
6	CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions. <i>Cell Reports Medicine</i> , 2021, 2, 100322.	6.5	5
7	In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. <i>Nature Communications</i> , 2021, 12, 3727.	12.8	43
8	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021, 7, veab057.	4.9	2
9	A Gut Reaction to SIV and SHIV Infection: Lower Dysregulation of Mucosal T Cells during Acute Infection Is Associated with Greater Viral Suppression during cART. <i>Viruses</i> , 2021, 13, 1609.	3.3	0
10	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	4.7	12
11	Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment. <i>PLoS Pathogens</i> , 2020, 16, e1008791.	4.7	25
12	Comparisons of Human Immunodeficiency Virus Type 1 Envelope Variants in Blood and Genital Fluids near the Time of Male-to-Female Transmission. <i>Journal of Virology</i> , 2019, 93, .	3.4	4
13	Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 557-566.	1.1	3
14	ISDB: a database toolkit for storing and analyzing viral integration site data. <i>Bioinformatics</i> , 2019, 35, 1073-1075.	4.1	6
15	Mucosal T Helper 17 and T Regulatory Cell Homeostasis Correlate with Acute Simian Immunodeficiency Virus Viremia and Responsiveness to Antiretroviral Therapy in Macaques. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 295-305.	1.1	10
16	Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1820-1831.	3.3	25
17	HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine. <i>Vaccine</i> , 2018, 36, 514-520.	3.8	15
18	No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 657-666.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2163-2177.	3.3	14
20	DNA Vaccineâ€“Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination. <i>Human Gene Therapy</i> , 2018, 29, 1029-1043.	2.7	12
21	Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. <i>PLoS Medicine</i> , 2018, 15, e1002537.	8.4	10
22	Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures. <i>Retrovirology</i> , 2017, 14, 6.	2.0	10
23	Clonal Expansion of Human Immunodeficiency Virusâ€“Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, S119-S127.	4.0	21
24	HIV Env conserved element DNA vaccine alters immunodominance in macaques. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2859-2871.	3.3	17
25	High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 234-245.	1.1	3
26	Patterns and rates of viral evolution in HIV-1 subtype B infected females and males. <i>PLoS ONE</i> , 2017, 12, e0182443.	2.5	16
27	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	2.5	27
28	Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1. <i>PLoS Pathogens</i> , 2017, 13, e1006703.	4.7	16
29	A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned. <i>BioResearch Open Access</i> , 2016, 5, 15-21.	2.6	5
30	HIV Transmission During Condomless Sex With a Seropositive Partner With Suppressed Infection. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2044.	7.4	1
31	DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV. <i>Journal of Immunology</i> , 2016, 197, 3999-4013.	0.8	33
32	Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8 + T Cells. <i>MBio</i> , 2016, 7, .	4.1	16
33	Lack of Resistance to Integrase Inhibitors among Antiretroviral-Naive Subjects with Primary HIV-1 Infection, 2007â€“2013. <i>Antiviral Therapy</i> , 2015, 20, 77-80.	1.0	59
34	How often does treatment of primary HIV lead to post-treatment control?. <i>Antiviral Therapy</i> , 2015, 20, 855-863.	1.0	27
35	Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses. <i>Journal of Visualized Experiments</i> , 2015, , e52610.	0.3	3
36	Composite Sequenceâ€“Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development. <i>Viruses</i> , 2015, 7, 5718-5735.	3.3	7

#	ARTICLE	IF	CITATIONS
37	p21WAF1/CIP1 RNA Expression in Highly HIV-1 Exposed, Uninfected Individuals. PLoS ONE, 2015, 10, e0119218.	2.5	3
38	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14658-14663.	7.1	154
39	Host Genetic and Viral Determinants of HIV-1 RNA Set Point among HIV-1 Seroconverters from Sub-Saharan Africa. Journal of Virology, 2015, 89, 2104-2111.	3.4	22
40	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. Journal of Translational Medicine, 2015, 13, 60.	4.4	84
41	Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection. Journal of Virology, 2015, 89, 10303-10318.	3.4	31
42	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. PLoS Computational Biology, 2015, 11, e1003973.	3.2	51
43	Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1391-1395.	3.0	10
44	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nature Medicine, 2015, 21, 1139-1141.	30.7	50
45	Comparison of Major and Minor Viral SNPs Identified through Single Template Sequencing and Pyrosequencing in Acute HIV-1 Infection. PLoS ONE, 2015, 10, e0135903.	2.5	20
46	Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques. PLoS ONE, 2014, 9, e86254.	2.5	47
47	An HIV Epidemic Model Based on Viral Load Dynamics: Value in Assessing Empirical Trends in HIV Virulence and Community Viral Load. PLoS Computational Biology, 2014, 10, e1003673.	3.2	27
48	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. EBioMedicine, 2014, 1, 37-45.	6.1	55
49	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. Journal of Translational Medicine, 2014, 12, 335.	4.4	13
50	HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment. Aids, 2014, 28, 1840-1844.	2.2	3
51	Increased Sequence Coverage through Combined Targeting of Variant and Conserved Epitopes Correlates with Control of HIV Replication. Journal of Virology, 2014, 88, 1354-1365.	3.4	18
52	The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8+ T cell responses. Virology, 2014, 450-451, 34-48.	2.4	10
53	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. AIDS Research and Human Retroviruses, 2014, 30, A25-A26.	1.1	0
54	Validation of an Oligonucleotide Ligation Assay for Quantification of Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by Use of Massively Parallel Sequencing. Journal of Clinical Microbiology, 2014, 52, 2320-2327.	3.9	17

#	ARTICLE	IF	CITATIONS
55	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. <i>Journal of Virology</i> , 2014, 88, 8242-8255.	3.4	55
56	Dendritic Cells Restore CD8 <sup>+</sup> T Cell Reactivity to Autologous HIV-1. <i>Journal of Virology</i> , 2014, 88, 9976-9990.	3.4	17
57	Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. <i>Science</i> , 2014, 345, 570-573.	12.6	573
58	Impact of Mutations in Highly Conserved Amino Acids of the HIV-1 Gag-p24 and Env-gp120 Proteins on Viral Replication in Different Genetic Backgrounds. <i>PLoS ONE</i> , 2014, 9, e94240.	2.5	18
59	HIV-1 Conserved Elements p24CE DNA Vaccine Induces Humoral Immune Responses with Broad Epitope Recognition in Macaques. <i>PLoS ONE</i> , 2014, 9, e111085.	2.5	37
60	CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants. <i>PLoS ONE</i> , 2014, 9, e111334.	2.5	9
61	Factors affecting relative fitness measurements in pairwise competition assays of human immunodeficiency viruses. <i>Journal of Virological Methods</i> , 2013, 194, 7-13.	2.1	5
62	HIV-1 Conserved-Element Vaccines: Relationship between Sequence Conservation and Replicative Capacity. <i>Journal of Virology</i> , 2013, 87, 5461-5467.	3.4	50
63	Inferring viral population structures using heteroduplex mobility and DNA sequence analyses. <i>Journal of Virological Methods</i> , 2013, 194, 169-177.	2.1	1
64	A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell culture. <i>Journal of Virological Methods</i> , 2013, 189, 157-166.	2.1	13
65	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. <i>PLoS Pathogens</i> , 2013, 9, e1003515.	4.7	109
66	Complex Patterns of Protease Inhibitor Resistance among Antiretroviral Treatment-Experienced HIV-2 Patients from Senegal: Implications for Second-Line Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2751-2760.	3.2	39
67	An Increasing Proportion of Monotypic HIV-1 DNA Sequences during Antiretroviral Treatment Suggests Proliferation of HIV-Infected Cells. <i>Journal of Virology</i> , 2013, 87, 1770-1778.	3.4	91
68	Partner Characteristics Predicting HIV-1 Set Point in Sexually Acquired HIV-1 Among African Seroconverters. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 164-171.	1.1	21
69	Selective Induction of CTL Helper Rather Than Killer Activity by Natural Epitope Variants Promotes Dendritic Cell-Mediated HIV-1 Dissemination. <i>Journal of Immunology</i> , 2013, 191, 2570-2580.	0.8	34
70	Quality Score Based Identification and Correction of Pyrosequencing Errors. <i>PLoS ONE</i> , 2013, 8, e73015.	2.5	9
71	HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice. <i>PLoS ONE</i> , 2013, 8, e60245.	2.5	44
72	Superior Control of HIV-1 Replication by CD8 <sup>+</sup> T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design. <i>PLoS ONE</i> , 2013, 8, e64405.	2.5	53

#	ARTICLE	IF	CITATIONS
73	Fitness Costs of Mutations at the HIV-1 Capsid Hexamerization Interface. <i>PLoS ONE</i> , 2013, 8, e66065.	2.5	26
74	Improved Detection of Rare HIV-1 Variants using 454 Pyrosequencing. <i>PLoS ONE</i> , 2013, 8, e76502.	2.5	12
75	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <i>Nature</i> , 2012, 490, 417-420.	27.8	405
76	CTL Responses of High Functional Avidity and Broad Variant Cross-Reactivity Are Associated with HIV Control. <i>PLoS ONE</i> , 2012, 7, e29717.	2.5	117
77	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	22.7	485
78	Mutation of HIV-1 Genomes in a Clinical Population Treated with the Mutagenic Nucleoside KP1461. <i>PLoS ONE</i> , 2011, 6, e15135.	2.5	71
79	Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial. <i>PLoS ONE</i> , 2011, 6, e16986.	2.5	80
80	HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa. <i>PLoS ONE</i> , 2011, 6, e22204.	2.5	26
81	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. <i>Nature Medicine</i> , 2011, 17, 366-371.	30.7	220
82	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011, 9, 208.	4.4	143
83	Demographic Processes Affect HIV-1 Evolution in Primary Infection before the Onset of Selective Processes. <i>Journal of Virology</i> , 2011, 85, 7523-7534.	3.4	86
84	Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission. <i>Science Translational Medicine</i> , 2011, 3, 77ra29.	12.4	265
85	CD39/Adenosine Pathway Is Involved in AIDS Progression. <i>PLoS Pathogens</i> , 2011, 7, e1002110.	4.7	154
86	Dynamics of Viral Evolution and CTL Responses in HIV-1 Infection. <i>PLoS ONE</i> , 2011, 6, e15639.	2.5	58
87	Increased Breadth and Depth of Cytotoxic T Lymphocytes Responses against HIV-1-B Nef by Inclusion of Epitope Variant Sequences. <i>PLoS ONE</i> , 2011, 6, e17969.	2.5	20
88	Genomewide Association Study for Determinants of HIV-1 Acquisition and Viral Set Point in HIV-1 Serodiscordant Couples with Quantified Virus Exposure. <i>PLoS ONE</i> , 2011, 6, e28632.	2.5	80
89	Restriction of HIV-1 Genotypes in Breast Milk Does Not Account for the Population Transmission Genetic Bottleneck That Occurs following Transmission. <i>PLoS ONE</i> , 2010, 5, e10213.	2.5	35
90	Amino-Acid Co-Variation in HIV-1 Gag Subtype C: HLA-Mediated Selection Pressure and Compensatory Dynamics. <i>PLoS ONE</i> , 2010, 5, e12463.	2.5	29

#	ARTICLE	IF	CITATIONS
91	Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk. PLoS ONE, 2010, 5, e12598.	2.5	129
92	Dendritic Cells Reveal a Broad Range of MHC Class I Epitopes for HIV-1 in Persons with Suppressed Viral Load on Antiretroviral Therapy. PLoS ONE, 2010, 5, e12936.	2.5	14
93	DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites. BioTechniques, 2010, 48, 405-408.	1.8	184
94	Genetic Analyses of HIV-1 Sequences Demonstrate Limited Compartmentalization in Breast Milk and Suggest Viral Replication within the Breast That Increases with Mastitis. Journal of Virology, 2010, 84, 10812-10819.	3.4	32
95	Virus-Specific CD8 <sup>+</sup> T-Cell Responses Better Define HIV Disease Progression than HLA Genotype. Journal of Virology, 2010, 84, 4461-4468.	3.4	50
96	HIV-1 Envelope Subregion Length Variation during Disease Progression. PLoS Pathogens, 2010, 6, e1001228.	4.7	79
97	Phylogenetic Analysis of Population-Based and Deep Sequencing Data to Identify Coevolving Sites in the nef Gene of HIV-1. Molecular Biology and Evolution, 2010, 27, 819-832.	8.9	59
98	HIV-1 Superinfection in the Antiretroviral Therapy Era: Are Seroconcordant Sexual Partners at Risk?. PLoS ONE, 2009, 4, e5690.	2.5	39
99	Fidelity of SNP Array Genotyping Using Epstein Barr Virus-Transformed B-Lymphocyte Cell Lines: Implications for Genome-Wide Association Studies. PLoS ONE, 2009, 4, e6915.	2.5	32
100	Rare HLA Drive Additional HIV Evolution Compared to More Frequent Alleles. AIDS Research and Human Retroviruses, 2009, 25, 297-303.	1.1	10
101	Monotypic Human Immunodeficiency Virus Type 1 Genotypes across the Uterine Cervix and in Blood Suggest Proliferation of Cells with Provirus. Journal of Virology, 2009, 83, 6020-6028.	3.4	49
102	Variable Fitness Impact of HIV-1 Escape Mutations to Cytotoxic T Lymphocyte (CTL) Response. PLoS Pathogens, 2009, 5, e1000365.	4.7	169
103	Emergence of Multiclass Drug Resistance in HIV-1 in Antiretroviral-Treated Individuals in Senegal: Implications for HIV Treatment in Resource-Limited West Africa. Clinical Infectious Diseases, 2009, 48, 476-483.	5.8	75
104	Preinfection Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T Lymphocytes Failed To Prevent HIV Type 1 Infection from Strains Genetically Unrelated to Viruses in Long-Term Exposed Partners. Journal of Virology, 2009, 83, 10821-10829.	3.4	11
105	Evidence for Limited Genetic Compartmentalization of HIV-1 between Lung and Blood. PLoS ONE, 2009, 4, e6949.	2.5	34
106	Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. Virology, 2008, 374, 229-233.	2.4	73
107	Male Genital Tract Compartmentalization of Human Immunodeficiency Virus Type 1 (HIV). AIDS Research and Human Retroviruses, 2008, 24, 561-571.	1.1	51
108	Evolution of CCR5 Use before and during Coreceptor Switching. Journal of Virology, 2008, 82, 11758-11766.	3.4	34

#	ARTICLE	IF	CITATIONS
109	Novel Cytotoxic T-Lymphocyte Escape Mutation by a Three-Amino-Acid Insertion in the Human Immunodeficiency Virus Type 1 p6 <sup>Pol</sup> and p6 <sup>Gag</sup> Late Domain Associated with Drug Resistance. <i>Journal of Virology</i> , 2008, 82, 495-502.	3.4	16
110	HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load. <i>Journal of Virology</i> , 2008, 82, 6434-6446.	3.4	126
111	Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag. <i>PLoS Computational Biology</i> , 2008, 4, e1000225.	3.2	116
112	HIV-1 Variation before Seroconversion in Men Who Have Sex with Men: Analysis of Acute/Early HIV Infection in the Multicenter AIDS Cohort Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1011-1015.	4.0	62
113	Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point. <i>Journal of Virology</i> , 2008, 82, 8548-8559.	3.4	152
114	Viral evolution and escape during primary human immunodeficiency virus-1 infection: implications for vaccine design. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 60-66.	3.8	8
115	Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. <i>Aids</i> , 2008, 22, 447-456.	2.2	29
116	Comparison of Immunogen Designs That Optimize Peptide Coverage: Reply to Fischer et al.. <i>PLoS Computational Biology</i> , 2008, 4, e25.	3.2	13
117	Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads. <i>PLoS ONE</i> , 2008, 3, e1424.	2.5	146
118	Lack of Evidence for Changing Virulence of HIV-1 in North America. <i>PLoS ONE</i> , 2008, 3, e1525.	2.5	34
119	Passive Transfer of HIV-1 Antibodies and Drug Resistant Virus during a Health Care Worker Accident: Implications for HCW Post-Exposure Management. <i>American Journal of Infectious Diseases</i> , 2008, 4, 244-256.	0.2	1
120	Decay of the HIV Reservoir in Patients Receiving Antiretroviral Therapy for Extended Periods: Implications for Eradication of Virus. <i>Journal of Infectious Diseases</i> , 2007, 195, 1762-1764.	4.0	180
121	Extensive Intrasubtype Recombination in South African Human Immunodeficiency Virus Type 1 Subtype C Infections. <i>Journal of Virology</i> , 2007, 81, 4492-4500.	3.4	62
122	Evolution of Human Immunodeficiency Virus Type 1 Cytotoxic T-Lymphocyte Epitopes: Fitness-Balanced Escape. <i>Journal of Virology</i> , 2007, 81, 12179-12188.	3.4	72
123	ViroBLAST: a stand-alone BLAST web server for flexible queries of multiple databases and user's datasets. <i>Bioinformatics</i> , 2007, 23, 2334-2336.	4.1	213
124	Coping with Viral Diversity in HIV Vaccine Design. <i>PLoS Computational Biology</i> , 2007, 3, e75.	3.2	83
125	HIV Type 1 Superinfection with a Dual-Tropic Virus and Rapid Progression to AIDS: A Case Report. <i>Clinical Infectious Diseases</i> , 2007, 45, 501-509.	5.8	35
126	HIV-1 Group M Conserved Elements Vaccine. <i>PLoS Pathogens</i> , 2007, 3, e157.	4.7	168



#	ARTICLE	IF	CITATIONS
127	Reconstruction and Function of Ancestral Center-of-Tree Human Immunodeficiency Virus Type 1 Proteins. <i>Journal of Virology</i> , 2007, 81, 8507-8514.	3.4	53
128	Control of Human Immunodeficiency Virus Type 1 Is Associated with HLA-B*13 and Targeting of Multiple Gag-Specific CD8 + T-Cell Epitopes. <i>Journal of Virology</i> , 2007, 81, 3667-3672.	3.4	138
129	Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations. <i>Science</i> , 2007, 315, 1583-1586.	12.6	234
130	Enhanced Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Nef-Specific T Cells Recognizing Multiple Variants in Early HIV-1 Infection. <i>Journal of Virology</i> , 2007, 81, 5225-5237.	3.4	45
131	Prevalence and Genetic Diversity of HIV Type 1 Subtypes A and D in Women Attending Antenatal Clinics in Uganda. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 755-760.	1.1	18
132	Compensatory Mutation Partially Restores Fitness and Delays Reversion of Escape Mutation within the Immunodominant HLA-B*5703-Restricted Gag Epitope in Chronic Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2007, 81, 8346-8351.	3.4	197
133	CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. <i>Nature Medicine</i> , 2007, 13, 46-53.	30.7	910
134	HIV-Specific Probabilistic Models of Protein Evolution. <i>PLoS ONE</i> , 2007, 2, e503.	2.5	96
135	Recognition of HIV-1 Peptides by Host CTL Is Related to HIV-1 Similarity to Human Proteins. <i>PLoS ONE</i> , 2007, 2, e823.	2.5	24
136	Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 3617-3623.	3.4	408
137	Sources of Variation in Ancestral Sequence Reconstruction for HIV-1 Envelope Genes. <i>Evolutionary Bioinformatics</i> , 2006, 2, 117693430600200.	1.2	1
138	EVOLUTION OF INTRAHOST HIV - 1 GENETIC DIVERSITY DURING CHRONIC INFECTION. <i>Evolution; International Journal of Organic Evolution</i> , 2006, 60, 1165-1176.	2.3	28
139	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. <i>Nature Immunology</i> , 2006, 7, 173-178.	14.5	209
140	Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. <i>Nature Immunology</i> , 2006, 7, 179-189.	14.5	91
141	Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. <i>Journal of Virological Methods</i> , 2006, 136, 118-125.	2.1	88
142	Differential Selection Pressure Exerted on HIV by CTL Targeting Identical Epitopes but Restricted by Distinct HLA Alleles from the Same HLA Supertype. <i>Journal of Immunology</i> , 2006, 177, 4699-4708.	0.8	79
143	Human Immunodeficiency Virus Type 1 env Evolves toward Ancestral States upon Transmission to a New Host. <i>Journal of Virology</i> , 2006, 80, 1637-1644.	3.4	103
144	Selection on the Human Immunodeficiency Virus Type 1 Proteome following Primary Infection. <i>Journal of Virology</i> , 2006, 80, 9519-9529.	3.4	118

#	ARTICLE	IF	CITATIONS
145	A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences. <i>Journal of Virology</i> , 2006, 80, 4698-4704.	3.4	124
146	Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus. <i>Journal of Virology</i> , 2005, 79, 9625-9634.	3.4	194
147	Nef Induces Multiple Genes Involved in Cholesterol Synthesis and Uptake in Human Immunodeficiency Virus Type 1-Infected T Cells. <i>Journal of Virology</i> , 2005, 79, 10053-10058.	3.4	89
148	Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression. <i>Journal of Virology</i> , 2005, 79, 9006-9018.	3.4	182
149	Preferential detection of HIV subtype C over subtype A in cervical cells from a dually infected woman. <i>Aids</i> , 2005, 19, 990-993.	2.2	10
150	HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. <i>Journal of Clinical Investigation</i> , 2005, 115, 3250-3255.	8.2	246
151	Influence of Random Genetic Drift on Human Immunodeficiency Virus Type 1 env Evolution During Chronic Infection. <i>Genetics</i> , 2004, 166, 1155-1164.	2.9	65
152	Pervasive Genomic Recombination of HIV-1 in Vivo Sequence data from this article have been deposited with the EMBL/GenBank Data Libraries under accession nos. AY496645, AY496646, AY496647, AY496648, AY496649, AY496650, AY496651, AY496652, AY496653, AY496654, AY496655, AY496656, AY496657, AY496658, AY496659, AY496660, AY496661, AY496662, AY496663, AY496664, AY496665, AY496666, AY496667, AY496668, AY496669, AY496670, AY496671, AY496672, AY496673, AY496674, AY496675, AY496676, AY496677, AY496678, AY496679, AY49. <i>Genetics</i> , 2004, 167, 1573-1583.	2.9	139
153	Clinical and immunological impact of HIV envelope V3 sequence variation after starting HIV initial triple antiretroviral therapy. <i>Aids</i> , 2004, 18, F1-F9.	2.2	80
154	Compartmentalization of Human Immunodeficiency Virus Type 1 between Blood Monocytes and CD4 + T Cells during Infection. <i>Journal of Virology</i> , 2004, 78, 7883-7893.	3.4	83
155	Immunogen sequence: the fourth tier of AIDS vaccine design. <i>Expert Review of Vaccines</i> , 2004, 3, S151-S159.	4.4	42
156	Differences in the Expressed HLA Class I Alleles Effect the Differential Clustering of HIV Type 1-Specific T Cell Responses in Infected Chinese and Caucasians. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 557-564.	1.1	14
157	Dual HIV-1 infection associated with rapid disease progression. <i>Lancet, The</i> , 2004, 363, 619-622.	13.7	189
158	Importance and detection of virus reservoirs and compartments of HIV infection. <i>Current Opinion in Microbiology</i> , 2003, 6, 410-416.	5.1	46
159	Evolutionary Indicators of Human Immunodeficiency Virus Type 1 Reservoirs and Compartments. <i>Journal of Virology</i> , 2003, 77, 5540-5546.	3.4	97
160	Improved Coreceptor Usage Prediction and Genotypic Monitoring of R5-to-X4 Transition by Motif Analysis of Human Immunodeficiency Virus Type 1 env V3 Loop Sequences. <i>Journal of Virology</i> , 2003, 77, 13376-13388.	3.4	390
161	Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2003, 77, 5721-5730.	3.4	93
162	Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences. <i>Journal of Virology</i> , 2003, 77, 7330-7340.	3.4	133

#	ARTICLE	IF	CITATIONS
163	Persistence of Extraordinarily Low Levels of Genetically Homogeneous Human Immunodeficiency Virus Type 1 in Exposed Seronegative Individuals. <i>Journal of Virology</i> , 2003, 77, 6108-6116.	3.4	83
164	Molecular Epidemiology of Dual HIV-1/HIV-2 Seropositive Adults from Senegal, West Africa. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 575-584.	1.1	34
165	Cellular Gene Expression upon Human Immunodeficiency Virus Type 1 Infection of CD4 + T-Cell Lines. <i>Journal of Virology</i> , 2003, 77, 1392-1402.	3.4	173
166	Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2003, 77, 3229-3237.	3.4	42
167	Predicting Demographic Group Structures Based on DNA Sequence Data. <i>Molecular Biology and Evolution</i> , 2003, 20, 1168-1180.	8.9	5
168	Consensus and Ancestral State HIV Vaccines. <i>Science</i> , 2003, 299, 1515c-1518.	12.6	121
169	Potential impact of recombination on sitewise approaches for detecting positive natural selection. <i>Genetical Research</i> , 2003, 81, 115-121.	0.9	158
170	Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14 <sup>+</sup> Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2002, 76, 707-716.	3.4	282
171	Virus Population Homogenization following Acute Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2002, 76, 11953-11959.	3.4	100
172	Molecular cloning and characterization of <i>Antheraea mylitta</i> cytoplasmic polyhedrosis virus genome segment 9. <i>Journal of General Virology</i> , 2002, 83, 1483-1491.	2.9	23
173	Selection for Human Immunodeficiency Virus Type 1 Recombinants in a Patient with Rapid Progression to AIDS. <i>Journal of Virology</i> , 2002, 76, 10674-10684.	3.4	68
174	Human Immunodeficiency Virus Type 1 Bound to B Cells: Relationship to Virus Replicating in CD4+ T Cells and Circulating in Plasma. <i>Journal of Virology</i> , 2002, 76, 8855-8863.	3.4	36
175	Curiously Modern DNA for a "250 Million-Year-Old" Bacterium. <i>Journal of Molecular Evolution</i> , 2002, 54, 134-137.	1.8	53
176	Substitution Model of Sequence Evolution for the Human Immunodeficiency Virus Type 1 Subtype B gp120 Gene over the C2-V5 Region. <i>Journal of Molecular Evolution</i> , 2001, 53, 55-62.	1.8	14
177	Cytopathicity of Human Immunodeficiency Virus Type 1 Primary Isolates Depends on Coreceptor Usage and Not Patient Disease Status. <i>Journal of Virology</i> , 2001, 75, 8842-8847.	3.4	42
178	Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection. <i>Journal of Experimental Medicine</i> , 2001, 193, 169-180.	8.5	363
179	Human Immunodeficiency Virus Type 1 Env Sequences from Calcutta in Eastern India: Identification of Features That Distinguish Subtype C Sequences in India from Other Subtype C Sequences. <i>Journal of Virology</i> , 2001, 75, 10479-10487.	3.4	90
180	Feline Immunodeficiency Virus Cell Entry. <i>Journal of Virology</i> , 2001, 75, 5433-5440.	3.4	33

#	ARTICLE	IF	CITATIONS
181	Should Patients with Drug-Resistant HIV-1 Continue to Receive Antiretroviral Therapy?. New England Journal of Medicine, 2001, 344, 520-522.	27.0	21
182	Re: Follow-up Study of Intra-host HIV Type 2 Variability Reveals Discontinuous Evolution of C2V3 Sequences. AIDS Research and Human Retroviruses, 2001, 17, 1563-1567.	1.1	2
183	Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nature Medicine, 2000, 6, 757-761.	30.7	404
184	Genetic Analysis of Viral Variants Selected in Transmission of Human Immunodeficiency Viruses to Newborns. AIDS Research and Human Retroviruses, 2000, 16, 1223-1233.	1.1	33
185	Perspective - Lethal Mutagenesis of HIV by Mutagenic Ribonucleoside Analogs. AIDS Research and Human Retroviruses, 2000, 16, 1-3.	1.1	72
186	Emerging genetic diversity of HIV-1 in South America. Aids, 2000, 14, 1785-1791.	2.2	44
187	Testing the Hypothesis of a Recombinant Origin of Human Immunodeficiency Virus Type 1 Subtype E. Journal of Virology, 2000, 74, 10752-10765.	3.4	65
188	Site-Directed Mutagenesis Using Uracil-Containing Double-Stranded DNA Templates and DpnI Digestion. BioTechniques, 1999, 27, 734-738.	1.8	18
189	Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 1999, 73, 10489-10502.	3.4	875
190	Antigen-specific cytokine responses in vaccinated <i>Macaca nemestrina</i> . Journal of Medical Primatology, 1999, 28, 181-189.	0.6	5
191	Evolution of Human Immunodeficiency Virus Type 1 Envelope Sequences in Infected Individuals with Differing Disease Progression Profiles. Virology, 1998, 241, 251-259.	2.4	88
192	Natural history of SIVmac BK28 and H824 infection in <i>Macaca nemestrina</i> . Journal of Medical Primatology, 1998, 27, 87-93.	0.6	5
193	Genetic Evaluation of Suspected Cases of Transient HIV-1 Infection of Infants. Science, 1998, 280, 1073-1077.	12.6	68
194	Anti-HIV Type 1 Memory Cytotoxic T Lymphocyte Responses Associated with Changes in CD4 <sup>+</sup> T Cell Numbers in Progression of HIV Type 1 Infection. AIDS Research and Human Retroviruses, 1998, 14, 1423-1433.	1.1	28
195	<b>Sequence Note</b> : Human Immunodeficiency Virus Type 1 Subtypes B and C Detected in New Zealand. AIDS Research and Human Retroviruses, 1998, 14, 1105-1108.	1.1	7
196	Evolution of a Simian Immunodeficiency Virus Pathogen. Journal of Virology, 1998, 72, 405-414.	3.4	37
197	Human Immunodeficiency Virus Type 1 Populations in Blood and Semen. Journal of Virology, 1998, 72, 617-623.	3.4	157
198	Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection. Journal of Virology, 1998, 72, 4288-4296.	3.4	131

#	ARTICLE	IF	CITATIONS
199	Quantitation of Target Molecules from Polymerase Chain Reaction-Based Limiting Dilution Assays. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 737-742.	1.1	137
200	Direct Amplification and Cloning of Up to 5-kb Lentivirus Genomes from Serum. <i>BioTechniques</i> , 1996, 21, 312-319.	1.8	3
201	Efficacy of an Inactivated Feline Leukemia Virus Vaccine. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 379-383.	1.1	25
202	Human Immunodeficiency Virus Type 1 Molecular Evolution and the Measure of Selection. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1681-1685.	1.1	37
203	Photonic detection of bacterial pathogens in living hosts. <i>Molecular Microbiology</i> , 1995, 18, 593-603.	2.5	524
204	The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand. <i>Aids</i> , 1995, 9, 851-858.	2.2	159
205	Mammalian cell/vaccinia virus expression vectors with increased stability of retroviral sequences in <i>Escherichia coli</i> : production of feline immunodeficiency virus envelope protein. <i>Gene</i> , 1995, 153, 197-202.	2.2	9
206	Rapid Molecular Epidemiology of Human Immunodeficiency Virus Transmission. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1081-1093.	1.1	58
207	Rapid Genetic Characterization of HIV Type 1 Strains from Four World Health Organization-Sponsored Vaccine Evaluation Sites Using a Heteroduplex Mobility Assay. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1345-1353.	1.1	94
208	V3 Region Polymorphisms in HIV-1 from Brazil: Prevalence of Subtype B Strains Divergent from North American/European Prototype and Detection of Subtype F. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 569-576.	1.1	153
209	Conserved V3 Loop Sequences and Transmission of Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1679-1684.	1.1	21
210	Early Pathogenesis of Disease Caused by SIV <sub>smmPBj14</sub> Molecular Clone 1.9 in Macaques. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 277-286.	1.1	52
211	Efficient amplification of HIV half-genomes from tissue DNA. <i>Nucleic Acids Research</i> , 1992, 20, 4933-4933.	14.5	19
212	Molecular Clones from a Non-Acutely Pathogenic Derivative of SIV <sub>smmPBj14</sub> : Characterization and Comparison to Acutely Pathogenic Clones. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1179-1187.	1.1	17
213	Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonyl-methoxyethyl)adenine (PMEA). <i>Antiviral Research</i> , 1991, 16, 77-92.	4.1	27
214	Selective impairment of humoral immunity in feline leukemia virus-induced immunodeficiency. <i>Veterinary Immunology and Immunopathology</i> , 1991, 28, 183-200.	1.2	8
215	Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14. <i>Nature</i> , 1990, 345, 636-640.	27.8	250
216	Selection against CpG dinucleotides in lentiviral genes: a possible role of methylation in regulation of viral expression. <i>Nucleic Acids Research</i> , 1990, 18, 5793-5797.	14.5	68

#	ARTICLE	IF	CITATIONS
217	Therapy of Presymptomatic FeLV-Induced Immunodeficiency Syndrome with AZT in Combination with Alpha Interferon. <i>Annals of the New York Academy of Sciences</i> , 1990, 616, 258-269.	3.8	10
218	Induction of aplastic anemia by intra-bone marrow inoculation of a molecularly cloned feline retrovirus. <i>Leukemia Research</i> , 1989, 13, 745-755.	0.8	26
219	FeLV-FAIDS-induced immunodeficiency syndrome in cats. <i>Veterinary Immunology and Immunopathology</i> , 1989, 21, 25-37.	1.2	18
220	Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2â€²,3â€²-dideoxycytidine. <i>Antiviral Research</i> , 1989, 11, 147-160.	4.1	14
221	Transduction of endogenous envelope genes by feline leukaemia virus in vitro. <i>Nature</i> , 1988, 332, 731-734.	27.8	130
222	The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein. <i>Cell</i> , 1987, 49, 307-319.	28.9	199
223	Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses. <i>Nature</i> , 1987, 326, 610-613.	27.8	209
224	Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. <i>Cell</i> , 1986, 47, 37-47.	28.9	415
225	Disease-specific and tissue-specific production of unintegrated feline leukaemia virus variant DNA in feline AIDS. <i>Nature</i> , 1986, 319, 333-336.	27.8	206
226	Virologic Studies in a Case of Transfusion-Associated AIDS. <i>New England Journal of Medicine</i> , 1984, 311, 1419-1422.	27.0	60
227	Viral transduction of c-myc gene in naturally occurring feline leukaemias. <i>Nature</i> , 1984, 308, 856-858.	27.8	160
228	Nucleotide Sequence of the Envelope Gene of Gardner-Arnstein Feline Leukemia Virus B Reveals Unique Sequence Homologies with a Murine Mink Cell Focus-Forming Virus. <i>Journal of Virology</i> , 1983, 46, 871-880.	3.4	150
229	Cloned genomic segments of <i>Zea mays</i> homologous to zein mRNAs. <i>Gene</i> , 1981, 14, 205-215.	2.2	29
230	Sequence organization of feline leukemia virus DNA in infected cells. <i>Nucleic Acids Research</i> , 1980, 8, 3287-3305.	14.5	67
231	Satellite Ic: a possible link between the satellite DNAs of <i>D. virilis</i> and <i>D. melanogaster</i> . <i>Cell</i> , 1979, 17, 615-621.	28.9	14